Supporters, including veterans advocates like Marcus Luttrell, hail the potential lifesaving impact of psychedelic therapies, while medical experts warn that safety concerns require robust clinical evidence.

The report notes ibogaine’s traditional use and cardiovascular risks, emphasizes that no psychedelic has FDA approval yet, and points to state experiments with psychedelic-assisted therapy in places like Oregon and Colorado.

The piece includes a note clarifying newsroom disclosure: Barchart Insights did not hold positions in the securities mentioned and links to disclosure policies.

The article situates the development within a broader trend of political leaders and influential media figures shaping public policy discussions.

The piece contrasts Joe Rogan’s influence and rapprochement with Trump against Tucker Carlson’s continued criticisms in the evolving political dynamics.

The Associated Press contributed reporting and coverage for the article.

User comments accompany the piece, with critics accusing the president of insecurity and optics of the Oval Office moment, while observers discuss clapping and broader political discourse.

Healthcare cost and affordability context are noted as part of the policy discussion surrounding access to psychedelic therapies.

Sources cited include White House actions, media coverage, and responses from Compass Pathways, highlighting cross-cutting interest from government, media, and industry.

Compass Pathways’ stock movement and related biotech peers are mentioned as part of post-announcement market reaction.

Market reaction showed a notable stock dip and increased trading volume following the news.

In a White House Oval Office ceremony, President signs an executive order directing federal agencies to speed up reviews of certain psychedelic drugs, including ibogaine, to accelerate medical research and potential treatments for serious mental illness.